Skip to main content
OpenTrials
Completed

NCT Number: NCT01166243

The Fibrin Pad Liver Study

The objective of this study is to evaluate the safety and and hemostatic effectiveness of the Fibrin Pad (FP) versus standard of care treatment (SoC) in controlling parenchymal bleeding during hepatic surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Flinders Medical Centre, Bedford Park, South Australia, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects > 18 years of age, requiring elective or urgent, open hepatic surgery
  • Presence of an appropriate bleeding hepatic parenchymal Target Bleeding Site (TBS) as identified intra-operatively by the surgeon
  • Subjects must be willing to participate in the study, and provide written informed consent

Exclusion criteria

  • Subjects with any intra-operative findings identified by the surgeon that may preclude conduct of the study procedure
  • TBS is from large defects in arteries or veins where the injured vascular wall requires repair with maintenance of vessel patency and which would result in persistent exposure of the FP to blood flow and pressure during healing and absorption of the product
  • TBS with major arterial bleeding requiring suture or mechanical ligation
  • Subjects admitted for trauma surgery
  • Subject is a transplant patient for fulminant hepatic failure
  • Subject with TBS within an actively infected field
  • Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine
  • Subjects with known intolerance to blood products or to one of the components of the study product or is unwilling to receive blood products
  • Subjects who are known, current alcohol and / or drug abusers
  • Subjects who have participated in another investigational drug or device research study within 30 days of surgery
  • Female subjects who are pregnant or nursing

Treatment and study plan

Fibrin Pad

Biological

Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).

Standard of care

Procedure

Standard of Care is a composite of techniques/methods typically used by the surgeon to control bleeding.

Primary outcomes

  1. Proportion of subjects achieving hemostasis at the Target Bleeding Site (TBS).

    Time frame: Intra-operative

Secondary outcomes

  1. Proportion of subjects achieving hemostasis success at 10-minutes following randomization.

    Time frame: Intra-operative

  2. Absolute time to hemostasis

    Time frame: Intraoperative

  3. Subjects requiring re-treatment

    Time frame: Intraoperative

  4. Incidence of adverse events potentially related to re-bleeding at TBS

    Time frame: Intraoperative through 60 days

  5. Incidence of adverse events potentially related to thrombotic events

    Time frame: Intraoperative through 60 days

  6. Incidence of adverse events

    Time frame: Intraoperative through 60 days

Sponsors and collaborators

Lead sponsor

Ethicon, Inc.

Industry

Collaborators

  • OMRIX Biopharmaceuticals

Registry information

Official study title

A Phase III Randomized, Controlled, Superiority Study Evaluating the Fibrin Pad Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Elective Hepatic Surgery

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Jul 21, 2010
Registry last updated
Jan 20, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.